Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$1.51MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maria Zannes
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 57
- Beta
- -1.11
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -18.98
Financials
Revenue
$1.51M+115564.5%Net Income
$-3.37MEBITDA
$-3.29MFree Cash Flow
$-3.29MEPS (diluted)
$-9.60Shares Outstanding (diluted)
348.4K+5762.2%Operating Expenses
$3.22MCash & Debt
$2.43MRevenue by Segment (annual)
$4.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.16M | $-14.91M | $-129.90 |
| 2024 | $9.36M | $-9.04M | $-337.50 |
| 2023 | $2.53M | $-7.94M | $-409.50 |
| 2022 | $4.8K | $-8.15M | $-814.50 |
| 2021 | $0.00 | $-6.33M | $-1062.90 |
| 2020 | $0.00 | $-7.27M | $-445.50 |
| 2019 | $0.00 | $-3.31M | $-202.50 |
Valuation
BIAFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120-4.00%Social Signal Score
Mentions (2)
- Newsbusinesswire.com·5h ago·Positive
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
View source ↗ - Newsbenzinga.com·4d ago·Positive
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ:BIAFW), up nearly 20% late Thursday.
View source ↗
Earnings
Wed, Nov 18(in 8 weeks)
Consensus estimate $-31.50 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-9.60 vs $-31.50beat
- Fri, May 8$-0.81 vs $-2.40beat
- Fri, Mar 13$-1.11 vs $-2.70beat
- Fri, Nov 14$-4.74 vs $-2.70miss
- Thu, Aug 14$-5.10 vs $-3.00miss
- Thu, May 15$-4.80 vs $-4.80beat
Estimates and results for BIAF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIAF officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BIAF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.